Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer
Escalation of neoadjuvant CIT in TNBC increases toxicity and leads to significant dose reductions without affecting the improvement in pCR rate.
Authors
- Lucie Thibault (ORCID: https://orcid.org/0000-0001-9236-2356)
- Emmanuelle Arnaud
- Dalila MEZIANI
- Florence Lerebours (ORCID: https://orcid.org/0009-0006-1895-4269)
- Paul Henri Cottu (ORCID: https://orcid.org/0000-0001-6434-3932)
- D. Loirat
- Luc Cabel (ORCID: https://orcid.org/0000-0001-5515-9180)
- Pauline Vaflard (ORCID: https://orcid.org/0000-0002-4710-6895)
- Romain Desmaris (ORCID: https://orcid.org/0000-0003-2583-5162)
- T. Ramtohul
- Lu Wang (ORCID: https://orcid.org/0000-0002-0073-0666)
- J-Y Pierga
- J.-G. Féron (ORCID: https://orcid.org/0000-0002-3774-9352)
Institutions
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Institut Curie (FR)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1016/j.esmorw.2025.100157
- Citations
- 1
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Institut Curie